Clinical Trials Sponsored by Oxford Immunotec

Total 1822 results

Oxford Immunotec

Completed

Assessing the Ability of the T-SPOT®.TB Test (IQ) (IQ)

Tuberculosis

United States
Oxford Immunotec

Completed

Assessing the Ability of the T-SPOT®.TB Test (IQ)

Tuberculosis (TB)

South Africa
Oxford Immunotec

Completed

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays (PROTECT)

Infection in Solid Organ Transplant Recipients

United States, United Kingdom, Canada
Oxford Immunotec

Terminated

Lyme Test Indication Combinations (LyTIC) Study (LyTIC)

Lyme Disease

United States
Oxford Immunotec

Completed

Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation (REACT)

Infection

United States, Canada, Sweden
Oxford Immunotec

Completed

Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)

Tuberculosis

United States, South Africa
University Health Network, Toronto
Oxford Immunotec

Completed

Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations

Tuberculosis

Canada
St. Jude Children's Research Hospital
Oxford Immunotec

Terminated

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

CMV

United States
Immunotec Inc.

Completed

Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons

Sarcopenia | Aging

Canada
Immunotec Inc.

Recruiting

Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health

Mild Cognitive Impairment (MCI)

Canada
Immunotec Inc.

Terminated

Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients

NON-SMALL CELL LUNG CANCER

Canada
AIM ImmunoTech Inc.

Terminated

Safety Study of FluMist With and Without Ampligen

Influenza, Human

United States
AIM ImmunoTech Inc.

Completed

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

HIV Infection | HIV Seropositivity

United States
AIM ImmunoTech Inc.

Completed

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Chronic Fatigue Syndrome | Myalgic Encephalomyelitis
AIM ImmunoTech Inc.

Completed

Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

Severe Acute Respiratory Syndrome

Hong Kong
AIM ImmunoTech Inc.

Terminated

A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects

HIV Infections

United States
AIM ImmunoTech Inc.

Terminated

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

HIV Infection | HIV Seropositivity

United States
AIM ImmunoTech Inc.

Available

Ampligen in Chronic Fatigue Syndrome

Chronic Fatigue Syndrome

United States
Nova Southeastern University
Immunotec Inc.

Completed

Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior

Autism Spectrum Disorders

United States
ImmunoGen, Inc.

Completed

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Belgium, Spain, Israel, Australia, Ireland, Germany, Italy, Bulgaria, Czechia, Poland
Inmunotek S.L.

Completed

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa (T502)

Immune System Diseases

Spain
Inmunotek S.L.

Completed

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy (MG56)

Rhinitis | Rhinoconjunctivitis

Spain
Inmunotek S.L.

Completed

Evaluation of the Efficacy and Safety of MV140 (MV140)

Urinary Tract Infection Bacterial

Spain, United Kingdom
ImmunoGen, Inc.

Completed

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (IMGN901)

Multiple Myeloma

United States, Argentina
Inmunotek S.L.

Not yet recruiting

Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

Allergic Reaction | Allergic Skin Reaction | Allergy Pollen

Spain
Inmunotek S.L.

Not yet recruiting

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

Allergic Reaction | Allergic Skin Reaction | Allergy Pollen

Spain
ImmunoGen, Inc.

Recruiting

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
ImmunoGen, Inc.

Recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, Spain, United Kingdom, Belgium, Canada, Georgia
Inmunotek S.L.

Not yet recruiting

Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

Immune Response
Inmunotek S.L.

Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Rhinitis, Allergic | Rhinoconjunctivitis | Asthma, Allergic

Spain
ImmunoGen, Inc.

Active, not recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm

United States, Spain, Germany, Italy, France, United Kingdom
Inmunotek S.L.

Unknown

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy (MM09)

Rhinitis | Rhinoconjunctivitis

Spain
ImmunoGen, Inc.

Terminated

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Spain, Canada, United Kingdom
ImmunoGen, Inc.

Completed

A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

Solid Tumor

United States
ImmunoGen, Inc.

Completed

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

United States
ImmunoGen, Inc.

Not yet recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian Cancer | Folate Receptor-Alpha Positive

United States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
Inmunotek S.L.

Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Rhinitis, Allergic | Rhinoconjunctivitis | Asthma, Allergic

Spain
ImmunoGen, Inc.

Active, not recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
ImmunoGen, Inc.

Completed

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Belgium, Canada
Inmunotek S.L.

Active, not recruiting

Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD) (MV130)

Chronic Obstructive Pulmonary Disease (COPD)

Spain
ImmunoGen, Inc.

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors (IMGN853-0401)

Tumors

United States, Canada
Inmunotek S.L.

Withdrawn

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel (Bacmune)

Covid19

Mexico
ImmunoGen, Inc.

Completed

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Inmunotek S.L.

Completed

Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts (MM09)

Immune System Diseases

Spain
ImmunoGen, Inc.

Completed

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Switzerland
ImmunoGen, Inc.

Terminated

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

EGFR Positive Solid Tumors

United States
ImmunoGen, Inc.

Withdrawn

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Stomach Neoplasms | Metastatic or Locally Advanced Gastric Cancer | Metastatic or Local Advanced GE Junction Cancer

United States
ImmunoGen, Inc.

Completed

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Ovarian Cancer | SCLC | Merkel Cell Carcinoma

United States, United Kingdom
ImmunoGen, Inc.

Completed

IMGN901 in Combination With Lenalidomide and Dexamethasone

Multiple Myeloma

United States
ImmunoGen, Inc.

Completed

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

Pancreatic Cancer | Non-colorectal Cancer

United States

3

Subscribe